Showing 1 to 2 of 2 results


JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics
The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...
JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics
The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...
Progress
44% Bias Score

Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.

Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.
Progress
40% Bias Score
Showing 1 to 2 of 2 results